| Literature DB >> 28534839 |
Yue Zhou1, Na Zhang2, Shan Tang3, Xiaoqian Qi4, Lijiao Zhao5, Rugang Zhong6, Yongzhen Peng7.
Abstract
Protein kinase CK2 has been considered as an attractive therapeutic target of cancer therapy. The tricyclic quinoline compound CX-4945 is the first representative of CK2 inhibitors used in human clinical trials. The binding of non-2,6-naphtyridine substituted compounds 27e (IC50 > 500 nM) and 27h (IC50 > 1000 nM) to CK2 is abolished. However, the unbinding mechanisms due to the key pharmacophore group replacement of compounds 27e and 27h are unveiled. In the present work, combined computational analysis was performed to investigate the underlying structural basis of the low-affinity of two systems. As indicated in the results, the loss of hydrogen bonds between the non-2,6-naphtyridine and the hinge region destroyed the proper recognition of the two complexes. Besides, the allosteric mechanisms between the deviated ligands and the changed regions (G-loop, C-loop and β4/β5 loop) are proposed. Furthermore, energetic analysis was evaluated by detailed energy calculation and residue-based energy decomposition. More importantly, the summary of known polar pharmacophore groups elucidates the pivotal roles of hinge region sub-pocket in the binding of CK2 inhibitors. These results provide rational clues to the fragment-based design of more potent CK2 inhibitors.Entities:
Keywords: fragment-based design; inhibitor; pharmacophore group; protein kinase CK2; tricyclic quinoline compounds
Mesh:
Substances:
Year: 2017 PMID: 28534839 PMCID: PMC6154313 DOI: 10.3390/molecules22050840
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Binding modes of compounds (A) 27e and (B) 27h with CK2α based on molecular docking.
Figure 2The time dependence of RMSD of inhibitors (upper) and CK2α (lower) for CK2 in complex with compounds 27e and 27h.
Figure 3(A) Calculated per-residue B-factor of three complexes systems; (B) Superimposed average structures of CK2α–12 (gray), CK2α–27e (purple) and CK2α–27h (brown) complexes; (C) Time evolution of distances between NZ atoms of Lys68 and OE1 and OE2 atoms of Glu81; (D) Coupled interactions between C-loop and G-loop in CK2α–12 (gray), CK2α–27e (purple) and CK2α–27h (brown).
Figure 4Stable binding mode of compounds (A) 27e and (B) 27h compared to compound 12 (magenta); Distances between NZ atoms of Lys68 and (C) O1 and O2 atoms of compound 27e, (D) O1 and O2 atoms of compound 27h.
Energy terms of MM/GBSA results for three CK2α-inhibitor complexes systems.
| Energy Term (kcal/mol) | 12 | 27e | 27h |
|---|---|---|---|
| ΔEele | −100.93 ± 4.0 | −112.33 ± 3.3 | −93.01 ± 4.0 |
| ΔEvdw | −30.55 ± 3.0 | −37.76 ± 3.1 | −36.28 ± 2.5 |
| ΔEgas a | −131.48 ± 6.0 | −150.10 ± 5.7 | −129.29 ± 3.4 |
| ΔGnonpolar | −4.84 ± 0.12 | −5.59 ± 0.20 | −5.20 ± 0.10 |
| ΔGpolar | 89.96 ± 3.9 | 110.84 ± 3.6 | 92.73 ± 5.0 |
| ΔGsol b | 85.12 ± 3.9 | 105.25 ± 2.2 | 87.52 ± 3.5 |
| ΔGele c | −10.97 ± 2.7 | −1.50 ± 3.1 | −0.28 ± 2.2 |
| ΔGbinding d | −46.36 ± 3.2 | −44.85 ± 3.1 | −41.76 ± 3.0 |
| ΔΔGbinding | 0 | 1.51 | 4.60 |
a ΔEgas = ΔEele + ΔEvdw; b ΔGsol = ΔGpolar + ΔGnonpolar; c ΔGele = ΔEele + ΔGpolar; d ΔGbinding = ΔEele + ΔEvdw + ΔGsol.
Figure 5Residue-Based energy decomposition on critical residues for CK2 in complex with compounds 12 (black), 27e (purple) and 27h (brown).
Figure 6Chemical structures and IC50 values of the tricyclic quinolone analogs 12 (R = 3-chlorophenyl), 27e (R = phenylamino) and 27h (R = phenylamino).